Just when investors thought they had seen the worst of it, the delayed Fibrogen/Astrazeneca project faces another problem.
December promises big US decisions for Novartis, Astrazeneca and Fibrogen, as well as the FDA's first Covid-19 vaccine reviews.
Cardiac safety threatens to derail the company’s new anaemia pill, but should rival Fibrogen be celebrating?
Two successful pivotal trials with vadadustat put Akebia on track to file its novel anaemia pill by year end – hot on the heels of Fibrogen.
Coronavirus aside, biotech companies including Akebia, Blueprint, Genfit and TG Therapeutics are set for some important data readouts in the next couple of months.
A cardiac safety analysis should calm some concerns over Astrazeneca and Fibrogen’s new anaemia pill, though regulators’ views on the hugely complex programme remain…
Fibrogen investors’ nerves jangle as another key cardiovascular safety readout approaches for the anaemia project.
Questions about Akebia's disclosure of liver toxicity in a trial raise a red flag over vadadustat, the company's experimental anaemia treatment.